Keywords: Novartis, Tasigna, GIT, Sativex, GW Pharma, License, Gilenya, Multiple sclerosis, Afinitor, Pancreatic cancer

Novartis drops Ph III Tasigna trial for GIST; in-licenses Sativex; and reports new Gilenya data

Article | 11 April 2011

Print This

In what has been a couple of busy and mixed news days for Swiss drug major Novartis (NOVN: VX), this ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in